Evidence map›Paper›PMID 38666615›Full record

ArticleEmerging infectious diseases2024

COVID-19 Vaccination Site Accessibility, United States, December 11, 2020-March 29, 2022.

Randy Yee, David Carranza, Christine Kim, James Phillip Trinidad, James L Tobias, Roma Bhatkoti, Sachiko Kuwabara

Abstract read
In one paragraph

Article in Emerging infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Exploring COVID-19 Vaccine Decision Making: Insights from 'One-Shot Wonders' and 'Booster Enthusiasts'.International journal of environmental research and public health · 2024
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Randy Yee
David Carranza
Christine Kim
James Phillip Trinidad
James L Tobias
Roma Bhatkoti
Sachiko Kuwabara

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During December 11, 2020-March 29, 2022, the US government delivered ≈700 million doses of COVID-19 vaccine to vaccination sites, resulting in vaccination of ≈75% of US adults during that period. We evaluated accessibility of vaccination sites. Sites were accessible by walking within 15 minutes by 46.6% of persons, 30 minutes by 74.8%, 45 minutes by 82.8%, and 60 minutes by 86.7%. When limited to populations in counties with high social vulnerability, accessibility by walking was 55.3%, 81.1%, 86.7%, and 89.4%, respectively. By driving, lowest accessibility was 96.5% at 15 minutes. For urban/rural categories, the 15-minute walking accessibility between noncore and large central metropolitan areas ranged from 27.2% to 65.1%; driving accessibility was 79.9% to 99.5%. By 30 minutes driving accessibility for all urban/rural categories was >95.9%. Walking time variations across jurisdictions and between urban/rural areas indicate that potential gains could have been made by improving walkability or making transportation more readily available.

Indexed as

COVID-19COVID-19 VaccinesHealth Services AccessibilitySARS-CoV-2VaccinationHumansRural PopulationUnited StatesUrban PopulationWalkingCOVID-19 Vaccines2019 novel coronavirus diseaseaccessibilitycoronavirus diseaseCOVID-19GIS analysisrespiratory infectionsSARS-CoV-2severe acute respiratory syndrome coronavirus 2social vulnerability indexUnited Statesvaccination sitesvaccineviruseszoonoses

Identifiers

PMID38666615
PMCPMC11060460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.